Market Performance - The new stock index and the near-term new stock index fell by 4.51% and 4.61% respectively in the fifth week of January, leading the market decline[7] - Approximately 90% of constituent stocks in the new stock index experienced a decline, with the stock "Bibeite" dropping over 20%[7] Trading Activity - The trading activity in the new stock sector continued to decline, with a predicted decrease in the scale of unlocks in the first week of February[16] - The net active selling in the new stock sector reached 6.366 billion yuan, an increase of 2.690 billion yuan from the previous week[21] New Stock Performance - Two new stocks listed in the market with an average first-day increase of over 200%, specifically 276.44% for Hengyun Chang and 139.59% for Zhenshi Co.[36] - The two new stocks contributed to A/B class investors' single account returns of 419,300 yuan and 404,400 yuan, corresponding to a yield increase of 0.71‰ and 0.70‰ for a 500 million yuan scale account[1] Valuation Metrics - The price-to-earnings (PE) ratio for the new stock index increased by 0.95 to 78.21, while the near-term new stock index saw a significant rise of 24.94 to 183.43[13] - The price-to-book (PB) ratio for the new stock index was recorded at 5.47, corresponding to a historical percentile of 91.3%[15] Risk Factors - There is a risk of reduced winning rates in new stock subscriptions and compliance risks due to internal system imperfections in offline investor participation[41]

Group 1: A-share New Stock Offerings - This week (January 12 - January 16), there are two new stocks available for subscription in the A-share market: Aisheren on the Beijing Stock Exchange and Hengyun Chang on the Sci-Tech Innovation Board, with subscriptions starting on Monday and Friday respectively [1] Group 2: Aisheren Overview - Aisheren's issue price is 15.98 yuan per share, with a single account subscription limit of 761,300 shares [2] - The company focuses on medical health, primarily engaged in the R&D, production, and sales of disposable medical consumables for rehabilitation care and medical protection, providing products like medical care pads and surgical kits [2] - Aisheren has established four production bases in operation, three under construction, and two planned, positioning itself as a leading player in the domestic medical dressing industry [2] Group 3: Aisheren Financial Performance - For the fiscal years 2022 to 2024, Aisheren's projected revenues are 574 million yuan, 575 million yuan, and 692 million yuan, with net profits of 63 million yuan, 67 million yuan, and 81 million yuan respectively [3] Group 4: Aisheren Fundraising Purpose - The funds raised will be invested in the construction of the Kaipule Public Health Medical Supplies Industrial Park [4] Group 5: Hengyun Chang Overview - Hengyun Chang has a single account subscription limit of 4,000 shares, requiring a minimum market value of 40,000 yuan in the Shanghai market for maximum subscription [5] - The company is a leading supplier of core components for semiconductor equipment, focusing on the R&D, production, and sales of plasma RF power systems and related components [5] Group 6: Hengyun Chang Product Development - Hengyun Chang has developed three generations of products over ten years, with its semiconductor-grade plasma RF power systems starting mass delivery in the second half of 2020, breaking the foreign monopoly in this field [6] - The Bestda series supports 28nm processes, while the latest Aspen series supports advanced processes of 7-14nm, achieving performance metrics comparable to American competitors [6] Group 7: Hengyun Chang Financial Performance - For the fiscal years 2022 to 2024, Hengyun Chang's projected revenues are 158 million yuan, 325 million yuan, and 541 million yuan, with net profits of 26 million yuan, 80 million yuan, and 142 million yuan respectively [6] Group 8: Hengyun Chang Fundraising Purpose - The funds raised will be allocated to the industrialization of semiconductor RF power systems, the establishment of an intelligent production operation base for core components, a research and innovation center, a marketing and technical support center, and to supplement working capital [6]